Search results
Opaque industry secretly inflates prices for prescription drugs | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 23 hours agoAmericans are paying too much for prescription drugs.
Merck KGaA shares plunge after cancer drug hopeful fails
Reuters· 2 hours ago, opens new tab slumped 8.9% at the open on Tuesday after the diversified group late on Monday said a trial testing a head and neck cancer drug, previously seen as promising ...
How the Ozempic hormone works – and ways to boost it naturally
The Telegraph via Yahoo News· 2 hours agoThey have been the-most-talked-about drugs of the last decade, maybe even the century. The new...
Merck KGaA Shares Drop After Canceled Late-Stage Cancer Drug Study
Morningstar· 1 hour agoBy David Sachs Merck KGaA shares fell in early trading after the firm discontinued a late-stage trial for a cancer drug. At 0729 GMT, Merck shares were down 10.1% at EUR150.25 ...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 6 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data
BioPharma Dive via Yahoo Finance· 21 hours ago...Trial investigators described the shot as “well-tolerated,” although early data cuts had revealed...
Alnylam Soars on Positive Heart-Drug Data
The Wall Street Journal· 15 hours agoAlnylam Pharmaceuticals’ stock jumped over 35% after the company’s closely watched heart drug performed well in a late-stage clinical trial. The
Alnylam Stock Soars on Strong Results in Heart Drug Study
Investopedia via Yahoo Finance· 19 hours agoAlnylam Pharmaceuticals shares soared after the company announced a Phase-3 study of its treatment...
Wegovy-maker Novo Nordisk to spend $4.1 billion to boost US manufacturing
Reuters via Yahoo News· 15 hours agoConstruction of the plant at Novo's existing main U.S...Carolina, will be completed between 2027 and...
Novo fills in positive picture for preventive hemophilia drug
BioPharma Dive via Yahoo Finance· 21 hours agoPhase 3 trial results should support an approval application for the drug, which analysts view as a...